Press Releases

Certara Joins Veeva AI Partner Program to Simplify and Expedite Regulatory Submissions for Life Sciences

Oct 22, 2025, 07:09 AM by
Partnership simplifies digital data flows between Veeva RIM and Certara’s CoAuthor™ generative AI solution for regulatory and medical writing

RADNOR, PA– October 21, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced it has joined the Veeva AI Partner Program. The planned integration by Certara with Veeva RIM aims to significantly enhance document automation by simplifying digital data flows between existing content stored in Veeva RIM and CoAuthor’s generative AI technology.

Rapidly changing study data often poses a significant roadblock for regulatory writers – from preparing first drafts to submission ready documents. This scenario costs the industry valuable time and creates tension between writers and the individuals in charge of preparing data for submission. In addition, the application of generative AI requires access to relevant data in near real time to provide acceptable results. Providing seamless access to content between data preparer, technology, and writer is critical to meeting shrinking submission deadlines.

By joining the Veeva AI Partner Program, Certara will allow its customers using CoAuthor and Veeva RIM to seamlessly work in both systems. Using CoAuthor, regulatory writers can directly link their source files from Veeva RIM, eliminating the need to import them into CoAuthor. This integration will streamline the initial content sourcing process, improving collaboration between data providers and regulatory writers throughout the document draft life cycle.

“Medical writers are embracing generative AI like CoAuthor to cut first-draft time by 30%. The integration with Veeva Rim allows us to deliver a seamless, end-to-end regulatory writing experience that drives greater value,” said Christopher Bouton, Chief Technology Officer at Certara.

To learn more, visit the CoAuthor webpage.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at certara.com.

Certara Contact:

Sheila Rocchio

Sheila.Rocchio@certara.com

Media Contact:

Alyssa Horowitz

Certara@pancomm.com